Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Shattuck Labs will webcast September investor conference presentations with its CEO and CFO for live and replay access.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Shattuck Labs (STTK) will participate in two September healthcare investor conferences via fireside chats and one-on-one meetings.
Management, including CEO Taylor Schreiber and CFO Andrew Neill, will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026 at 11:00 AM ET and at the Cantor Global Healthcare Conference on September 9, 2026 at 3:55 PM ET. Live and replay webcasts will be available through the company’s investor relations website.
Details
News Market Reaction – STTK
On Sep 3, the first trading day after this news, STTK closed 0.72% above the previous close. Our momentum scanner recorded 9 alerts in the available session data.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Conference number
- 21st
- Wells Fargo Annual Healthcare Conference
- Presentation date
- September 8, 2026
- Wells Fargo Annual Healthcare Conference
- Presentation time
- 11:00 AM ET
- Wells Fargo Annual Healthcare Conference
- Presentation date
- September 9, 2026
- Cantor Global Healthcare Conference
- Presentation time
- 3:55 PM ET
- Cantor Global Healthcare Conference
- Replay availability
- 30 days
- Following the live presentations
Historical Context
-
Quarterly results, pipeline updates, and cash balance supported a modest positive reaction
-
Public offering priced at $4.00 per share with approximately $75 million gross proceeds
-
Proposed equity offering remained subject to market conditions and final terms
-
Warrant exercises were expected to generate roughly $54.9 million in gross proceeds
-
SL-325 showed favorable safety, receptor occupancy, and durable TL1A blockade
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:
Conference Details
Wells Fargo 21st Annual Healthcare Conference
Format: Fireside chat and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer
Presentation Date: September 8, 2026
Time: 11:00 AM ET
Webcast link: HERE
Cantor Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer
Presentation Date: September 9, 2026
Time: 3:55 PM ET
Webcast link: HERE
Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Shattuck Labs (STTK) present at the Wells Fargo 21st Annual Healthcare Conference?
Shattuck Labs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026 at 11:00 AM ET. The format includes a fireside chat and one-on-one meetings with management.
What are the details of Shattuck Labs (STTK) presentation at the Cantor Global Healthcare Conference?
Shattuck Labs is scheduled to present at the Cantor Global Healthcare Conference on September 9, 2026 at 3:55 PM ET. The company will participate in a fireside chat and one-on-one investor meetings.
Who from Shattuck Labs (STTK) will present at the September 2026 investor conferences?
The presenters are Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, and Andrew Neill, M.B.A., Chief Financial Officer. Both executives are listed as participants at the Wells Fargo and Cantor healthcare conferences.
How can investors access the Shattuck Labs (STTK) September 2026 conference webcasts?
Interested parties can access live audio webcasts of Shattuck Labs’ presentations via the Investor Relations section of www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.
Will replays of the Shattuck Labs (STTK) September investor presentations be available?
Yes. Replay webcasts of Shattuck Labs’ September investor conference presentations will be available for approximately 30 days after the live events through the company’s investor relations website.